Renal Cell Carcinoma

Clinical insights from a leader in kidney cancer research on the differences between clear cell and non–clear cell renal cell carcinoma.

A speedy review of an approval application for belzutifan has been undertaken by the FDA.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ulka Vaishampayan, MD, discussed the TIVO-3 study of tivozanib for patients with recurrent advanced renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandy Liu, MD, discussed the potency of immunotherapy and tyrosine kinase inhibitor combinations for patients with metastatic renal cell carcinoma.

Robert J. Motzer, MD, discusses unmet needs and looks to the future of treatment for patients with clear cell renal cell carcinoma.

Expert perspectives on how adverse events differ among the available clear cell renal cell carcinoma treatment options.

In the second article of a 2-part series, Sumanta K. Pal, MD, leads a discussion on what therapies physicians consider in the later-line settings for treatment of patients with advanced renal cell carcinoma.

A key opinion leader in the field of renal cell carcinoma offers clinical insight on treatment sequencing strategies.

A comprehensive review of second-line treatment options for patients with clear cell renal cell carcinoma.

In the second article of a 2-part series, Rana McKay, MD, discussed follow-up analyses of the phase 3 CheckMate 9ER trial that showed the benefit of nivolumab plus cabozantinib vs sunitinib for patients with advanced renal cell carcinoma.

Eric A. Singer, MD, MS, discusses future developments that could improve the utilization of adjuvant therapy for high-risk renal cell carcinoma.

Robert J. Motzer, MD, provides insights on factors that influence treatment decisions for patients with clear cell renal cell carcinoma.

Continuing discussion on advanced renal cell carcinoma, Robert J. Motzer, MD, reviews recent clinical trial data presented at ASCO 2023 and KCRS 2023.

An expert medical oncologist reviews recent data updates on lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Robert J. Motzer, MD, provides an overview of the CLEAR trial investigating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandy Liu, MD, discussed the frontline tyrosine kinase inhibitor/immune checkpoint inhibitor regimens and how to manage toxicities related to these regimens.

In an interview with Targeted Oncology, Bradley A. McGregor, MD, discussed the main takeaways from a phase 3 study of cabozantinib, nivolumab, and ipilimumab for patients with renal cell carcinoma with variant histologies.

According to Eric Jonasch, MD, promising findings from LITESPARK-005 may help with a goal of getting belzutifan FDA approval for patients with refractory renal cell carcinoma.

In the first article of a 2-part series, Sumanta K. Pal, MD, leads a discussion on considerations for the treatment of patients with relapsed/refractory renal cell carcinoma in the third-line setting.

Several immunotherapies are now approved for the management of metastatic RCC. However, immunotherapy-based combination regimens are associated with high rates of treatment-related toxicities and do not yield objective responses in a significant proportion of patients.

Eric A. Singer, MD, MS, discusses which patients he believes would benefit most from adjuvant therapy for high-risk renal cell carcinoma.

Concluding the discussion, Dr Rana McKay discusses the current state of advanced RCC, potential breakthroughs, and best practices for optimal patient outcomes.

Rana McKay, MD, provides insights into decision-making strategies and consideration for treatment sequencing in advanced RCC.

Discussion on triplet therapy regimens in advanced RCC and how progressing therapeutic studies can impact its future use.

Expert perspective on CheckMate 9ER quality of life data and treatment implications for patients with advanced RCC.

Centering discussion on the CheckMate 9ER trial, Dr. McKay shares perspective of recent follow-up data of nivolumab + cabozantinib in frontline advanced RCC.

Reflection on biomarkers, treatment resistance, and other unmet needs in 1L treatment of advanced RCC by Rana R. McKay, MD.

Dr Rana McKay provides insight on preferred therapeutic options for first-line treatment of RCC and how patient risk stratification influences decision making.

Rana R. McKay, MD, reflects on the landscape of advanced RCC, discusses histology, subsets of kidney cancer, and IMDC criteria for prognostic stratification.

As the first study of its kind, KEYNOTE-B61 has demonstrated potential to move pembrolizumab plus lenvatinib earlier in the treatment of non-clear cell renal cell carcinoma.